Session Time: 4:30pm-6:00pm
Presentation Time: 5:18pm-5:30pm
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach to HCV positive grafts. Herein, we present our experience with DAAs in HCV positive patients who receive an HCV positive graft.
Methods: Multi-center, retrospective review of patients from July, 2015 till present. HCV positive patients receiving an HCV positive liver and then treated with DAAs were included.
Results: 20 HCV positive patients received an HCV positive graft. 10 patients have started HCV treatment at the time of this abstract.
|Genotype||Pre-Treatment Viral Load||Treatment Regimen in Weeks||Response||Adverse Events|
DAAs were initiated an average of 6 months post OLT. All were on Tacrolimus based immunosupression and none required adjustment.
Discussion: Historically, HCV grafts are more likely to be discarded compared to HCV negative grafts. Our series demonstrates a favorable response to Sofosbuvir based regimens. The patients in our series were given anti-virals regardless of graft fibrosis or viral load. Our series is unique in describing empiric initiation of DAAs in HCV patients receiving a HCV graft. While further studies are required to confirm our experience, the remarkable response to DAAs may shift our approach to HCV positive grafts.
CITATION INFORMATION: Kapila N, Zervos B, Ismail B, Lindenmeyer C, Sanghi V, Menon K, Schnickel G, Rivas J, Reino D, Tzakis A. A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Kapila N, Zervos B, Ismail B, Lindenmeyer C, Sanghi V, Menon K, Schnickel G, Rivas J, Reino D, Tzakis A. A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/a-multi-center-experience-of-direct-acting-anti-viral-agents-in-hcv-positive-patients-receiving-hcv-positive-livers/. Accessed July 2, 2020.
« Back to 2017 American Transplant Congress